Cetuximab

Phase 3

PFIZER (PFE)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

10mo

PFEPhase 2$142.7B

Cetuximab Phase 2 Results Expected

Cetuximab• Squamous Cell Carcinoma of the Head and Neck (SCCHN)35

Dec 31Estimated

CT.gov

00%

3mo

PFEPhase 2$142.7B

Cetuximab Phase 2 Results Expected

Cetuximab• Squamous Cell Carcinoma of the Head and Neck (SCCHN)107

Jun 1Estimated

CT.gov

00%

PFEPhase 2$142.7B

Cetuximab Phase 2 Results Expected

Cetuximab• Squamous Cell Carcinoma of the Head and Neck (SCCHN)107

Apr 12Estimated

CT.gov

00%

PFEPhase 3$142.7B

✓Positive

cetuximab Phase 3 Results Expected

Cetuximab• Squamous Cell Carcinoma of the Head and Neck (SCCHN)400

Apr 3Estimated

CT.gov

Competitive Landscape

0 competitors in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

View Full Landscape

Drug Information

Target Indication

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Clinical Trial

NCT02499120

Last updated: 12/29/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

PFE

PFIZER

Healthcare•North America•NASDAQ

Related Pipeline

13 valent pneumococcal conjugate vaccine with Polysorbate 80Phase 3

Vaccines, Pneumococcal

Cyclosporine APhase 3

Renal Transplantation

Insulin LisproPhase 3

Diabetes Mellitus

DVS-233 SR (desvenlafaxine sustained release )Phase 3

Major Depressive Disorder

MeropenemPhase 3

Complicated Intra-abdominal Infections

View full pipeline